We examined the effectiveness of human papillomavirus vaccination by dose number and spacing against incident genital warts in a cohort of 64,517 female health-plan enrollees in the United States during 2006-2012. Eligible recipients were classified into groups by regimen: 0, 1, 2 (<6 months apart), 2 (≥6 months apart), or 3 doses. They were followed until a genital wart diagnosis, loss to follow-up, or the end of study. Propensity score weights were used to balance baseline differences across groups. To account for latent genital warts before vaccination, we applied 6-and 12-month buffer periods from last and first vaccine dose, respectively. Incidence rates and hazard ratios were calculated using Poisson regression and Cox models. The propensity score-weighted incidence rate per 100,000 person-years was 762 among unvaccinated participants. Using 6-and 12-month buffer periods, respectively, incidence rates were 641 and 257 for 1 dose, 760 and 577 for the 2-dose (<6-month interval) regimen, 313 and 194 for the 2-dose (≥6-month interval) regimen, and 199 and 162 among 3-dose vaccinees; vaccine effectiveness was 68% and 76% for the 2-dose (≥6-month interval) regimen and 77% and 80% in 3-dose vaccinees compared with unvaccinated participants. Vaccine effectiveness was not significant among vaccinees receiving 1-dose and 2-dose (<6-month interval) regimens compared with unvaccinated participants. Our findings contribute to a better understanding of the real-world effectiveness of HPV vaccination. genital warts; human papillomavirus vaccine; vaccine effectiveness Abbreviations: 4vHPV, quadrivalent human papillomavirus vaccine; CI, confidence interval; GW, genital warts; HPV, human papillomavirus; HR, hazard ratio.
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Currently available human papillomavirus (HPV) vaccines were licensed and recommended based on clinical vaccine trials of 3-dose schedules-given at 0-, 1-to 2-, and 6-month intervals-that showed high efficacy against cervical precancers caused by types targeted by the vaccines (1) (2) (3) . In clinical trials of the quadrivalent HPV vaccine (4vHPV) among women, perprotocol efficacy against genital warts (GW) caused by 2 targeted types was 100% while the efficacy in the intention-to-treat population was 73% (4) . After licensure, population effectiveness of vaccination against early HPV outcomes was demonstrated in a variety of studies worldwide, with ecologic studies providing some of the strongest evidence of population impact. Notably, ecologic studies from Australia, where first-dose vaccine coverage among girls aged 12-13 years exceeded 80% shortly after implementation of a national vaccination program that included catch-up vaccination for women through age 26 years, showed near elimination of incident GW (5, 6) . The studies also noted reductions in GW incidence in unvaccinated women and heterosexual men in Australia, suggesting herd effects (7) .
The high efficacy and high antibody titers achieved after a 3-dose schedule led to interest in evaluating alternative and reduced-dose schedules for HPV vaccination. Immunobridging studies of 2-dose vaccination with an interval of 6 months or longer indicated noninferior antibody response among recipients aged 9-14 years compared with those aged 16-26 years who were vaccinated with a standard 3-dose schedule (8) (9) (10) . Based on these data, many regulatory agencies approved a 2-dose schedule for immunocompetent girls aged 9-14 years (11, 12) .
Population effectiveness of reduced-dose schedules against HPV-associated clinical outcomes has been evaluated in several countries (13) (14) (15) (16) (17) (18) (19) . However, findings from these studies vary and are difficult to interpret in light of methodological challenges.
In particular, published studies to date, which are based primarily on national registries, had limited ability to adjust for potential confounding arising from baseline differences among unvaccinated individuals, individuals who completed the series as recommended, and those receiving less than 3 doses of vaccine. We examined the effectiveness of 1, 2 (with different intervals between doses), and 3 doses of 4vHPV vaccine against incident GW in female enrollees of health plans in 3 states using propensity score weights to minimize group differences.
METHODS

Study design, setting, and population
The retrospective cohort study was conducted in 3 regions (Colorado, Georgia, Pacific Northwest) served by Kaiser Permanente, an integrated health-care delivery system operating nationwide. Each site extracted data from electronic medical records and administrative data to create a cohort of eligible participants. This study was reviewed and approved by the institutional review boards at each participating Kaiser site.
The study period was from August 1, 2006, to September 30, 2012. The study population consisted of female enrollees in the three health plans on August 1, 2006, which was the start of HPV vaccine introduction, or who reached age 11 years while enrolled in one of the health plans after this date, and who were aged 15-22 years at any time during the study period. Additionally, female enrollees had to have evidence of sexual activity (as determined using the 2012 Healthcare Effectiveness Data and Information Set definition) at any time from age 11 years to the end of the study period. The Healthcare Effectiveness Data and Information Set determines sexual activity based on coded diagnoses and procedures that might indicate sexual activity, such as a pregnancy test, birth-control dispensing, or diagnosis of a sexually transmitted infection (20) . The later of August 1, 2006 , or the 11th birthday is considered the individual's index date. Female enrollees with a GW diagnosis prior to or on August 1, 2006, or who had any diagnosis code for immunocompromised state or cancer during January 1, 1997, to September 30, 2012, were excluded (Web Appendix 1, available at https://academic.oup.com/aje).
Outcome measurement
The outcome was incident GW diagnosis during the study period. Cases were first identified from electronic medical records using a previously described case-definition algorithm based on a combination of diagnosis codes for warts (International Classification of Diseases, Ninth Revision, codes 078.10, 078.11, and 078.19), the specialty of the diagnosing provider, and sexually transmitted infection tests ordered at the encounter (21) . Chart reviews were performed for all individuals who met the electronic case definition and only the chart-confirmed GW cases were used in the analysis. The chart-confirmed GW diagnosis date was used if it differed from the electronically identified diagnosis date.
Exposure assessment
Exposure groups were defined as eligible female enrollees who received 1 dose, 2 doses (<6 months apart), 2 doses (≥6 months apart), or 3 doses of HPV vaccine during the study period. The comparison group consisted of those who did not receive an HPV vaccine during the study period. To ensure similar calendar and observation time between vaccinated and unvaccinated groups, a proxy "vaccination" date was generated for those who were unvaccinated to match the distribution of the date of first vaccine dose among vaccinated individuals. An individual's exposed time began at the date of the last vaccination dose for vaccinated individuals and at the proxy date for unvaccinated individuals.
Statistical analysis
We used multiple-group propensity score weighting to balance potential confounders among the study groups. Propensity scores were estimated using logistic regression. Covariates were selected based on association with vaccination or GW diagnosis and included race/ethnicity, health plan (site), age at enrollment in the health plan, age at beginning of study period, age at first evidence of probable sexual activity (as defined by Healthcare Effectiveness Data and Information Set criteria), age at first dose of HPV vaccine (or proxy date), indicator for whether the person was continuously enrolled from index date to the end of the study period, months enrolled in the health plan, indicator for whether the person had any preventive health visits, Medicaid enrollment, oral contraceptive use, or history of tests for pregnancy, chlamydia, or gonorrhea. Missing values for race/ethnicity were imputed based on the individual's US Census probabilities of being non-Hispanic white, non-Hispanic black, Hispanic, or other.
For each individual, propensity score regression estimated the probabilities of belonging to each of the 5 vaccine groups. An individual's propensity score weight was calculated as the inverse of her estimated probability for the vaccine group in which she actually was. This weighting allows estimation of the average treatment effect. Balance with respect to each variable included in the propensity score regression models was assessed using absolute standardized mean difference before and after weighting (22) .
Exposed person-time was calculated as the difference between the date of an individual's final vaccine dose (or proxy date) and the date of incident GW diagnosis, date lost to follow-up, or end of the study period. Incidence rates of GW per 100,000 person-years and corresponding 95% confidence intervals were calculated for each vaccination group. All analyses were propensity score weighted in order to account for baseline differences across vaccination groups; unweighted results are presented for comparison. In separate analyses, 2 buffer periods were applied to exclude GW cases due to infection with GW HPV type prior to vaccination: a 6-month buffer after the final vaccine dose (n = 64,517) and a 12-month buffer after the first vaccine dose (n = 62,057). Incidence rates were estimated using Poisson regression, and jackknife confidence intervals were estimated for propensity score-weighted results. Additionally, we used a Cox proportional hazards regression model to estimate hazard ratios and 95% confidence intervals of incident GW for vaccinated enrollees relative to those who were unvaccinated. Vaccine effectiveness was calculated as (1 − hazard ratio) × 100. Health plan (site) was included in all models to account for geographic clustering. Stata, version 13 (StataCorp LP, College Station, Texas), was used for all analyses.
From August 1, 2006 , to September 30, 2012, a total of 64,517 eligible female enrollees were identified across the 3 sites (Table 1) . Overall, most (64.9%) were non-Hispanic white, 14.5% were non-Hispanic black, and 12.2% were Hispanic; racial/ethnic distribution varied by site. Mean age at the beginning of the study period (index age) was 16.5 (standard deviation, 3.4) years, and mean age at the beginning of continuous enrollment in the health plan was 10.7 (standard deviation, 5.7) years overall. On average, eligible female enrollees had been members of their health plan for 68.2 (standard deviation, 48.4) months prior to first vaccination (or proxy vaccination date for unvaccinated enrollees). Across all sites, 9.1% received only 1 dose, 4.2% received 2 doses <6 months apart, 4.2% received 2 doses ≥6 months apart, 33.5% received 3 or more doses, and 48.9% were not vaccinated, with the proportion unvaccinated ranging from 39.0% to 61.5%.
Among those who received 2 doses, the median time between doses 1 and 2 was 179 days. In the 3-dose group the median time between doses 1 and 2 was 88 days, and the median time between doses 2 and 3 was 157 days. Among the 32,954 female enrollees who received ≥1 dose during the study period, the majority in all sites (58%, 66%, and 68%) completed the 3-dose series. The average length of study follow-up from first vaccine dose (or proxy date) was approximately 2.7 years and varied across groups: Mean follow-up was 1.7 years in the unvaccinated group, 2.2 years in the 1-dose and 2-dose <6-month interval groups, 3.5 years in the 2-dose ≥6-month interval group, and 4.2 years in the 3-dose group.
Characteristics differed significantly across vaccination groups prior to propensity score weighting (Table 2) . Unvaccinated individuals, on average, were older at the time of healthplan enrollment and at study start date. They were also less likely to have received a preventive care visit during enrollment prior to proxy vaccination date (unvaccinated = 46.4% versus 3 doses = 65.0%). Additionally, unvaccinated individuals were more likely to be non-Hispanic black (17.1%) and less likely to be non-Hispanic white (64.6%), relative to individuals who received all 3 doses (10.9% black, 69.7% white). Propensity score weighting significantly improved covariate balance across vaccination groups: The absolute standardized mean difference was less than or equal to 0.10 for covariates after weighting.
During the study period with a 6-month buffer from the final vaccine dose, 725 chart-confirmed GW cases were included in the analysis. Crude GW incidence rate per 100,000 personyears was highest in the unvaccinated group (991, 95% , and 199 in the 3-dose group (95% CI: 153, 264). Cumulative incidence curves showed that the 3-dose group and those who received 2 doses ≥6 months apart had similar and substantially lower GW incidence compared with the other groups ( Figure 1A ). Hazard ratios were estimated using a Cox proportional hazards model; we present propensity score-weighted and unweighted results for comparison (Table 4) . Propensity score-weighted estimates indicated that GW risk was significantly reduced among individuals who received 2 doses of vaccine with a ≥6-month interval (hazard ratio (HR) = 0.32; 95% CI: 0.17, 0.59) or those who received 3 doses (HR = 0.23; 95% CI: 0.17, 0.31) compared with the unvaccinated. Vaccine effectiveness was 77% (95% CI: 69, 83) for 3-dose vaccination and 68% (95% CI: 41, 83) for 2-dose vaccination with a ≥6-month interval between doses. One-dose vaccination did not significantly reduce the risk of incident GW in weighted analysis (HR = 0.81; 95% CI: 0.60, 1.08), nor did 2 doses with <6-month interval (HR = 0.91; 95% CI: 0.59, 1.41). The 3-dose and 2-dose with ≥6-month interval groups both had significantly lower incidence rates relative to the 2-dose with <6-month interval group. The incidence rates for the groups receiving 3 doses or 2 doses with ≥6-month intervals were not significantly different. The unweighted analysis yielded similar results, although the magnitude of the effects was larger in the unweighted analysis.
During the study period with a 12-month buffer from first vaccine dose, 57 GW cases included in the 6-month buffer analysis among the 1-dose and 2-dose <6-month interval groups were excluded, for a total of 668 chart-confirmed cases with GW diagnosis. Propensity score-weighted results indicated significantly reduced GW incidence in the 1-dose, 2-dose ≥6-month interval, and 3-dose groups compared with the unvaccinated. Incidence rates were 257 per 100,000 person-years (95% CI: 162, 432) in the 1-dose group, 194 (95% CI: 108, 386) in the group receiving 2 doses with ≥6-month intervals, and 162 (95% CI: 124, 215) in the 3-dose group (Table 3) . Differences between unvaccinated and vaccinated individuals were larger overall than in the 6-month buffer analyses, and the incidence rates across the vaccinated groups were more similar ( Figure 1B) . Propensity score-weighted hazard ratio estimates indicated significantly lower GW risk among individuals who received 1 dose (HR = 0.32, 95% CI: 0.20, 0.52), 2 doses with ≥6-month intervals (HR = 0.24, 95% CI: 0.13, 0.44), or 3 doses (HR = 0.20, 95% CI: 0.15, 0.27) compared with the unvaccinated (Table 4) . Vaccine effectiveness was 80% (95% CI: 73, 85) for 3 doses, 76% (95% CI: 56, 87) for 2 doses with at least 6 months between doses, and 68% (95% CI: 48, 80) for 1 dose. As in the 6-month buffer analysis, 2-dose vaccination with an interval less than 6 months did not significantly reduce the risk of incident GW (HR = 0.72; 95% CI: 0.41, 1.25) compared with the unvaccinated or other vaccine groups. Incidence rates in the groups receiving 3 doses or 2 doses with ≥6-month intervals were not statistically significantly different.
DISCUSSION
In this multisite, observational study of US female healthplan enrollees receiving HPV vaccine during routine clinical encounters, we evaluated 4vHPV effectiveness against GW by number of vaccine doses as well as the interval between doses for those who received 2 doses of vaccine. Consistent with previous reports, we observed significant reductions in incident GW diagnosis in those who completed the 3-dose series as recommended at the time of the study. We also found that compared with no vaccination, vaccine effectiveness among those who received 2 doses differed by interval between doses, and that receipt of 2 doses with a minimum 6-month interval between doses was as effective as receiving 3 doses while receipt of 2 doses <6 months apart did not significantly reduce the risk of incident GW. Female recipients of only 1 dose had a lower risk of GW; however, this was not significantly different from the risk among unvaccinated female enrollees. HPV vaccine effectiveness has been reported to be dosedependent in previous studies (13, (15) (16) (17) (18) . Because these studies were conducted in settings with routine 3-dose vaccination, however, vaccine spacing in the majority of those who received only 2 doses was 1-2 months as recommended, thus limiting the ability to examine the effect of longer intervals between 2 doses. Similar to our findings, a study by Blomberg et al. (14) showed that 2-dose effectiveness of 4vHPV vaccination against GW increased with increasing number of months between doses, and it was as effective as a 3-dose series when doses were spaced about 6 months apart. Another observational study of girls who participated in a 4vHPV vaccine trial in India found lower rates of incident infection in girls who received 2 doses ≥6 months apart compared with those who received the second dose at 2 months. Incidence in the longer-interval 2-dose group was also similar to that among girls who received 3 doses, but the results did not reach statistical significance (23) . In contrast, Brotherton et al. (19) found that 2-dose vaccination was less effective than the 3-dose series against cervical lesions and that there was no difference according to dose interval among girls who received 2 doses.
An important limitation of dose-effectiveness studies to date, and one that likely contributes to the discrepant findings, is that none were able to account adequately for the differences in demographic characteristics and sexual behaviors that are strongly associated with receipt of HPV vaccine as well as clinical outcomes. To our knowledge, this is the first study of HPV vaccine effectiveness to use propensity score methods to balance vaccinated and unvaccinated female participants on a wide range of factors known to be associated with vaccination and incident GW. The observed baseline differences among the vaccine groups and the consistently larger hazard ratio estimates in the unweighted analysis compared with the propensity score-weighted analyses highlight the importance of accounting for potential confounders.
Two-dose HPV vaccine schedules with intervals of ≥6 months between doses have been approved for girls starting the series before age 15 years in some countries, including the United States (12), based on noninferior antibody response of an extended 2-dose schedule in young adolescents compared with a 3-dose schedule in young adult women in which efficacy was demonstrated in clinical trials (8) (9) (10) . Immunogenicity studies have found lower antibody titers achieved when 2 doses are administered at 0 and 1-2 months compared with 0 and 6 months (24). These results are consistent with the understanding that at least 4-6 months is required for memory B cells to mature into the high-affinity B cells that have a critical role in the immune response to HPV vaccines. Because vaccine dose groups were defined without age restrictions in this study, our findings offer preliminary evidence that an extended 2-dose schedule may be effective among young adults even when the first dose is administered after age 15. This is consistent with results from a Danish registry study that did not find a significant difference in VE for an extended 2-dose schedule among individuals who received the first dose before and after 16 years of age (14) .
This study has some limitations. First, characterization of sexual behavior from administrative data may have resulted in misclassification in either direction. Vaccination and case status may have also been misclassified for those who were vaccinated or who got care for GW outside the health plan. Second, while propensity score weighting was used to balance vaccination groups on demographic and medical characteristics, the groups may have differed with respect to unmeasured or omitted variables. Third, although this study represents a large sample of female enrollees of a nationwide, managed health plan, our results may not be generalizable to the entire population. Finally, both definitions of buffer periods used in this study have limitations. Applying buffer periods from the last vaccine dose allows exposure time to begin at the same point relative to the cumulative vaccine series received for all individuals. However, the length of time from the beginning of the vaccine sequence to the beginning of exposure time varies across treatment groups. Given that individuals in the 1-and 2-dose groups had less time during the vaccine sequence for latent GW infections to emerge prior to case counting, vaccine effectiveness in these groups may be underestimated compared to that in the 3-dose group. A 12-month buffer period from the first dose equalizes the time across groups in which individuals may receive a diagnosis arising from latent GW infection. However, this approach allows case counting to begin prior to receipt of the last vaccine dose in those who received >1 dose with long intervals between each dose.
Overall, our findings contribute to a better understanding of the real-world effectiveness of 4vHPV against GW, and also illustrate the challenges of estimating vaccine effectiveness by number of doses. Importantly, this study adds to the limited evidence suggesting that the degree of protection is dependent on the length of time between doses, and that with sufficient spacing between doses, 2-dose vaccination confers similar benefits to those of 3 doses. unrelated research studies. The other authors report no conflicts.
